Newbury Pharmaceuticals AB (OSTO:NEWBRY) EV-to-EBIT : -4.05 (As of Jun. 04, 2024)

Newbury Pharmaceuticals AB EV-to-EBIT Chart

Newbury Pharmaceuticals AB Quarterly Data
	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EV-to-EBIT	Get a 7-Day Free Trial									-5.29	-3.52	-3.58	-3.30	-4.74

Competitive Comparison of Newbury Pharmaceuticals AB's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Newbury Pharmaceuticals AB's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Newbury Pharmaceuticals AB's EV-to-EBIT falls into.

Newbury Pharmaceuticals AB EV-to-EBIT Calculation

Newbury Pharmaceuticals AB's EV-to-EBIT for today is calculated as:

Newbury Pharmaceuticals AB's current Enterprise Value is kr66.85 Mil.
Newbury Pharmaceuticals AB's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-16.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newbury Pharmaceuticals AB  (OSTO:NEWBRY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Newbury Pharmaceuticals AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

Newbury Pharmaceuticals AB's Enterprise Value for the quarter that ended in Feb. 2024 was kr78.31 Mil.
Newbury Pharmaceuticals AB's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-16.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newbury Pharmaceuticals AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Newbury Pharmaceuticals AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Newbury Pharmaceuticals AB (OSTO:NEWBRY) Business Description